A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics, and effect of RC108-ADC for injeciton
in subjects with c-Met positive advanced malignant solid tumors.